Assessing Ovarian Reserve

  • Yasmin Gosiengfiao
  • Veronica Gomez-LoboEmail author


Female cancer survivors are at risk for decreased fertility and early menopause usually due to the impact of therapy on oocytes and ovaries. The ability to assess ovarian reserve or the number of oocytes in the ovaries may significantly improve care by elucidating which therapies and patients are at a higher risk of ovarian failure, as well as which patients would benefit most from fertility preservation therapies. Current markers of ovarian reserve were developed and have been well studied in infertile populations; thus, their utility in children and adolescents who undergo cancer therapy remains unknown. This chapter will discuss currently used markers of fertility and ovarian reserve and their implications in girls with cancer.


Ovarian reserve Premature ovarian insufficiency Infertility Antral follicle count Anti-Mullerian hormone 


  1. 1.
    Byrne J, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992;166(3):788–93.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Green DM, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2374–81.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Thomas-Teinturier C, et al. Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature. Hum Reprod. 2013;28(2):488–95.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Zegers-Hochschild F, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril. 2009;92(5):1520–4.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod. 1996;11(7):1484–6.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Practice committee of the american society for reproductive medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9–17.CrossRefGoogle Scholar
  7. 7.
    Goodwin PJ, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365–70.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–29.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Koyama H, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403–9.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Domingues TS, Rocha AM, Serafini PC. Tests for ovarian reserve: reliability and utility. Curr Opin Obstet Gynecol. 2010;22(4):271–6.PubMedPubMedCentralGoogle Scholar
  11. 11.
    ACOG Committee Opinion No. 349. November 2006: menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol. 2006;108(5):1323–8.CrossRefGoogle Scholar
  12. 12.
    Burger HG. The endocrinology of the menopause. Maturitas. 1996;23(2):129–36.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab. 1987;65(6):1231–7.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Burger HG, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab. 1995;80(12):3537–45.PubMedPubMedCentralGoogle Scholar
  15. 15.
    La Marca A, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Kelsey TW, et al. A validated model of serum anti-Mullerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Tsepelidis S, et al. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod. 2007;22(7):1837–40.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    van Rooij IA, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83(4):979–87.CrossRefGoogle Scholar
  19. 19.
    Broer SL, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011;96(8):2532–9.CrossRefGoogle Scholar
  20. 20.
    Hagen CP, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):5003–10.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(2):129–40.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Miyoshi Y, Yasuda K, Tachibana M, Yoshida H, Miyashita E, Miyamura T, Hashii Y, Hashimoto K, Kimura T, Ozono K. Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment. Clin Pediatr Endocrinol. 2016;25(4):119–26.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Gupta AA, Lee Chong A, Deveault C, Traubici J, Maloney AM, Knight S, Lorenzo A, Allen L. Anti-Müllerian hormone in female adolescent cancer patients before, during, and after completion of therapy: a pilot feasibility study. J Pediatr Adolesc Gynecol. 2016;29(6):599–603.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    van der Kooi AL, van den Heuvel-Eibrink MM, van Noortwijk A, Neggers SJ, Pluijm SM, van Dulmen-den Broeder E, van Dorp W, Laven JS. Longitudinal follow-up in female childhood cancer survivors: no signs of accelerated ovarian function loss. Hum Reprod. 2017;32(1):193–200.PubMedPubMedCentralGoogle Scholar
  25. 25.
    van Beek RD, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin’s lymphoma during childhood. J Clin Endocrinol Metab. 2007;92(10):3869–74.CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Lie Fong S, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod. 2009;24(4):982–90.CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Krawczuk-Rybak M, Leszczynska E, Poznanska M, Zelazowska-Rutkowska B, Wysocka J. Anti-müllerian hormone as a sensitive marker of ovarian function in young cancer survivors. Int J Endocrinol. 2013;2013:125080.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Elchuri SV, Patterson BC, Brown M, Bedient C, Record E, Wasilewski-Masker K, Mertens AC, Meacham LR. Low anti-Müllerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy. J Pediatr Adolesc Gynecol. 2016;29(4):393–9.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Dillon KE, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99(2):477–83.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Su HI. Measuring ovarian function in young cancer survivors. Minerva Endocrinol. 2010;35(4):259–70.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Anders C, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Investig. 2008;26(3):286–95.CrossRefGoogle Scholar
  32. 32.
    Birch Petersen K, et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Hum Reprod. 2015;30(10):2364–75.CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Bath LE, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003;18(11):2368–74.CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701.CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Larsen EC, et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab. 2003;88(11):5307–14.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hematology, Oncology & Stem Cell TransplantationAnn & Robert H. Lurie Children’s Hospital of ChicagoChicagoUSA
  2. 2.Department of Women and Infant Services, Department of SurgeryMedStar Washington Hospital Center, Children’s National Medical CenterWashingtonUSA

Personalised recommendations